



Date: 11th December, 2025

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204 | Eiko

Subject: Outcome of the Board Meeting

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended ("SEBI LODR Regulations"), we hereby inform you that the Board of Directors of Eiko LifeSciences Limited ("the Company") at their Meeting held today, i.e., Thursday, 11th December, 2025, inter-alia considered and approved:

1. Acquisition of **51% equity shares of M/s. SSM Formulations Private Limited** (SSM Formulations / Target Company"), a company operating in business of Pharmaceuticals. Accordingly, SSM Formulations would become a Subsidiary Company of Eiko LifeSciences Limited.


*The details required under Regulation 30 of the LODR Regulations read with the SEBI Master Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are given in **Annexure A** to this letter.*

2. Raising of funds through issue and allotment of upto **33,00,000 (Thirty-Three Lakh) Warrants**, each Warrant convertible into 1 (one) Equity Share of the Face Value of Rs. 10/- (Rupees Ten Only) to persons belonging to Promoter, Promoter Group and Non- Promoter / Public as per **Annexure B** on preferential basis in terms of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") at **Issue Price of Rs. 55/- (Rupees Fifty-Five Only)** including Premium of Rs. 45/- (Rupees Forty-Five) per warrant (being the price not less than the minimum price determined with reference to the Relevant Date in accordance with Regulation 164 of the ICDR Regulations aggregating upto maximum amount of **Rs. 18,15,00,000/- (Rupees Eighteen Crores and Fifteen Lakhs only)** subject to the approval of regulatory/ statutory authorities and the Members of the Company at ensuing Extra Ordinary General Meeting.

*The details required under Regulation 30 of the LODR Regulations read with the SEBI Master Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are given in **Annexure C** to this letter.*

3. Raising of funds through issue and allotment of up to **6,75,000 (Six Lakhs Seventy-Five Thousand)** Equity Shares of the Face Value of Rs. 10/- (Rupees Ten Only) each to persons belonging to Promoter, Promoter Group and Non- Promoter / Public as per **Annexure D** on preferential basis in terms of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") at Issue Price of **Rs. 55/- (Rupees Fifty-Five Only)** including Premium of Rs. 45/- (Rupees Forty-Five) per Share (being the price not less than the minimum price determined with reference to the Relevant Date in accordance with Regulation 164 of the ICDR Regulations aggregating up to maximum amount of **Rs. 3,71,25,000/- (Rupees Three Crore Seventy-One Lakhs Twenty-Five only)** subject to the approval of regulatory/ statutory authorities and the Members of the Company at the ensuing Extra Ordinary General Meeting.

*The details required under Regulation 30 of the LODR Regulations read with the SEBI Master Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are given in **Annexure E** to this letter.*

- 
4. Draft Notice of Extra Ordinary General Meeting ("EGM") of the Company to be held on **Wednesday, 07th January 2026 at 03:00 pm**, through VC/OAVM, to seek necessary approval of the members of the Company.

The notice of the said EGM will be sent separately to the Members of the Company and will also be available on the Company's website at www.eikolifesciences.com and on the website of the stock exchange i.e. Bombay Stock Exchange of India Limited at www.bseindia.com, in due course.

5. The Board of Directors have appointed Mr. Shravan Gupta, Practicing Company Secretary (ACS-9990), as the scrutinizer to scrutinize the e-voting process in a fair and transparent manner for the purpose of EGM of the Company.

The Meeting was commenced at 09:50 AM and concluded at 10:35 AM.

Please take the same on your records.

For Eiko Lifesciences Limited

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A 36190



ANNEXURE A

Details as per the SEBI Master Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

1	Name of the target entity, details in brief such as size, turnover etc	<p>M/s. SSM Formulations Private Limited ("Target Company")</p> <p>Brief Details of business: The Target Company is primarily engaged in the business of manufacturing pharmaceutical products.</p> <p>The Target Company was registered under Companies Act, 1956 on 13th December 2012 under Company Identification Number: U24233MH2012PTC237383</p> <p>Turnover of Last 3 Financial Years:</p> <p>FY 2024-25: 27,65,06,754</p> <p>FY 2023-24: 41,41,02,661</p> <p>FY 2022-23: 50,82,00,394</p>
2	<p>Whether the acquisition falls within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arm's length"</p>	<p>The Transaction is not a related party transaction.</p>
3	Industry to which the entity being acquired belongs	<p>Pharmaceuticals</p>
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>The acquisition constitutes a strategic forward-integration move into pharmaceutical formulations, aimed at diversifying the product portfolio and capturing higher value across the pharmaceutical supply chain. It will consolidate company's market position in specialty chemicals, pharmaceutical intermediates and APIs, while expanding the existing API portfolio and providing access to new niche molecules and client segments. The transaction is expected to generate operational synergies and economies of scale, and the target entity's business aligns directly with the Company's core line of activity.</p>
5	Brief details of any governmental or regulatory approvals required for the acquisition;	<p>No governmental or regulatory approvals required for the acquisition.</p>
6	Indicative time period for completion of the acquisition	<p>NA</p>



7	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
8	Cost of acquisition and/or the price at which the shares are acquired	Total Consideration of INR 18,00,00,000/- (Eighteen Crores only)
9	Percentage of shareholding / control acquired and / or number of shares acquired	71,71,950 shares, being 51% holding of the Target Company over a defined period.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	For brief background and turnover refer point “(1)” above. Date of incorporation of the Target Company: 23/12/2012 Country Presence: India



ANNEXURE B

List of Proposed Allottees - Warrants

Sr. No.	Names of the Proposed Allottees	Category (Promoter / Non-promoter)	No. of Warrants	Outcome of the subscription/ Investment amount (INR) (Approx.)	Issue price/allotted price (in case of convertibles) (INR)
1	Lenus Finvest Private Limited	Promoter Group	1,50,000	82,50,000	55.00
2	Bhavesh Dhirajlal Tanna	Promoter	16,00,000	8,80,00,000	55.00
3	V Square Pharmachem Private Limited	Non-Promoter	10,00,000	5,50,00,000	55.00
4	Vaibhaviben Nitinkumar Akhani	Non-Promoter	1,00,000	55,00,000	55.00
5	Murlidhar Mohanlal Lakhiani HUF	Non-Promoter	1,00,000	55,00,000	55.00
6	Amir Hasanali Lalani	Non-Promoter	1,50,000	82,50,000	55.00
7	Utkarsh C Vartak	Non-Promoter	2,00,000	1,10,00,000	55.00
	Total		33,00,000	18,15,00,000	



ANNEXURE C

Details as per the SEBI Master Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Details
1	Types and Nature of securities proposed to be Issued	Issue of up to 33,00,000 (Thirty-Three Lakhs) Warrants, each Warrant convertible into 1 (one) Equity Share of the Face Value of Rs. 10/- (Rupees Ten Only) to persons belonging to Promoter, Promoter Group and Non- Promoter / Public as per Annexure B on preferential basis
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue of warrants in accordance with the SEBI (ICDR) Regulation 2018 read with the Companies Act, 2013 and rules made thereunder.
3	Total number of Securities proposed to be issued or the total amount for which the securities will be issued	Issue of upto 33,00,000 (Thirty-Three Lakhs) Share Warrants at a price of Rs. 55/- (Rupees Fifty-Five) per Warrant, each convertible into 1 (one) Equity Share of face value of Rs. 10/- (Rupees Ten Only) each fully paid up at a premium of Rs. 45/- (Rupees Forty-Five) each per warrant ("Issue Price") in cash, for an aggregate consideration of up maximum amount of Rs. 18,15,00,000/- (Rupees Eighteen Crores and Fifteen Lakhs only)
4	Issue Price	Rs. 55/- (Rupees Fifty-Five Only) including Premium of Rs. 45/- (Rupees Forty-Five)
5	Additional details Names of the Allottees No. of Investors Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	As per Annexure B 7, (Seven) [As per Annexure B] Each Warrant would be convertible into, or exchangeable, at an option of Proposed Allottee(s) of warrants (as under Annexure B), within a maximum period of 18 months from the date of allotment of Warrants into equivalent number of fully paid-up equity share of face value of Rs. 10/- each of the Company. An amount equivalent to at least 25% of the warrant issue price shall be payable upfront along with the application and the balance 75% shall be payable by the Proposed Allottee(s) of warrants on the exercise of option of conversion of the warrant(s), such Conversion shall take place in in one or more tranches. Not Applicable



ANNEXURE D

List of Proposed Allottees – Equity Shares

Sr. No.	Names of Proposed Allottees	Category (Promoter / Non-Promoter)	No. of Equity shares	Outcome of the subscription/ Investment amount (INR) (Approx.)	Issue price/allotted price (INR)
1	Lenus Finvest Private Limited	Promoter Group	1,75,000	96,25,000	55.00
2	Bhavesb Dhirajlal Tanna	Promoter	4,50,000	2,47,50,000	55.00
3	Vaibhaviben Nitinkumar Akhani	Non-Promoter	50,000	27,50,000	55.00
TOTAL			6,75,000	3,71,25,000	



ANNEXURE E

Details as per the SEBI Master Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Details
1	Types and Nature of securities proposed to be Issued	Issue of up to 6,75,000 (Six Lakhs Seventy-Five Thousand) Equity Shares of the Face Value of Rs. 10/- (Rupees Ten Only) each to persons belonging to Promoter, Promoter Group and Non- Promoter / Public as per Annexure D on preferential basis
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue of Equity Shares in accordance with the SEBI ICDR Regulations, 2018 read with the Companies Act, 2013 and rules made thereunder
3	Total number of Securities proposed to be issued or the total amount for which the securities will be issued	Issue of up to 6,75,000 (Six Lakhs Seventy-Five Thousand) Equity Shares of face value of Rs. 10/- (Rupees Ten Only) each fully paid up at a price price of Rs. 55/- (Rupees Fifty-Five) per Warrant, each convertible into 1 (one) Equity Share of face value of Rs. 10/- (Rupees Ten Only) each fully paid up at a premium of Rs. 45/- (Rupees Forty-Five) each per warrant ("Issue Price") in cash, for an aggregate consideration of up to Rs. 3,71,25,000/- (Rupees Three Crore, Seventy-One Lakhs Twenty-Five only)
4	Issue Price	Rs. 55/- (Rupees Fifty-Five Only) including Premium of Rs. 45/- (Rupees Forty-Five)
5	Additional details Names of the Allottees No. of Investors Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	As per Annexure D 3 (Three) [As per Annexure D] As per Annexure D Not Applicable